Page contentsPage contents Key facts Decision Key facts Active substance oxybutynin Therapeutic area Renal and urinary disorders Decision number EMA/PE/0000182297 PIP number EMA/PE/0000182297 Pharmaceutical form(s) Vaginal delivery system Condition(s) / indication(s) Treatment of myoneurogenic bladder disorders Route(s) of administration Vaginal use Contact for public enquiries LiGalli B.V.Email: info@ligalli.health Tel: +31 850806821 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 06/12/2024 Compliance check done No Decision EMA/PE/0000182297: EMA decision of 6 December 2024 on the granting of a product specific waiver for oxybutyninAdopted Reference Number: EMADOC-1700519818-1790205 English (EN) (238.71 KB - PDF)First published: 17/12/2025 View Share this page